Avian influenza virus A H5N1 infection spiraled into a global pandemic in 2009, due to mutations in highly infectious H1N1 strain. The outbreak and spread of the pandemic echoes the need for ensuring robust health care systems and development of effective biomedical tools e.g. vaccines which shall help to respond beyond the spatial and temporal limitations. National Biopharma Mission is committed to support development of vaccine candidates for influenza.

Name of grantee

Development Phase Supported

Environmental and Health Risk Management Plan (EHRMP)


Pre-Clinical studies

Click Here